IOVA
14.45USD
+3.46 (+31.48%)
52-week high $15.30
52-week low $1.76
Iovance Biotherapeutics surged 31.5 percent while the Nasdaq edged down 0.1 percent, showing a sharp move against the broader market. The jump followed the company's decision to raise its 2026 revenue and target 60 percent growth. Investors pushed the shares to a new 52-week high on the stronger long-term sales outlook.
Raised 2026 revenue , eyes 60% growth
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
The company is still unprofitable (net income is negative).
Price is 48% above the 1-month average and 101% above the 3-month average — recent trend is up.
Over the last 3 months it is about 228% ahead of the market — a leading move.
Buying momentum has picked up over the last few days.
The recent run looks stretched — a pause would not be surprising.
Today's is 4.5x the 20-day average and the stock is up — buyers are showing up.
has been rising (5-day avg is 1.5x the 20-day) and the stock is up — accumulation.
A single day's movement doesn't change the long-term direction.
It's okay not to decide right now.
This content is compiled from publicly available data for reference only. It is not investment advice or a stock recommendation. All investment decisions and their outcomes are your own responsibility.